Search research articles
Contact Us
Filters
Showing results (61-70 of 76) with videos related to
Page
of 8
Sort By:
Leukemia
|
February 26, 2013
A G polymorphism in the CRBN gene acts as a biomarker of response to treatment with lenalidomide in low/int-1 risk MDS without del(5q)
V Sardnal, A Rouquette, S Kaltenbach, et al.
Leukemia Research
|
February 13, 2010
Clinical management of myelodysplastic syndromes: update of SIE, SIES, GITMO practice guidelines
V Santini, P E Alessandrino, E Angelucci, et al.
Blood
|
April 16, 1998
Proliferation signaling and activation of Shc, p21Ras, and Myc via tyrosine 764 of human granulocyte colony-stimulating factor receptor
J P de Koning, A A Soede-Bobok, A M Schelen, et al.
Leukemia
|
November 7, 2013
Expression of nucleoside-metabolizing enzymes in myelodysplastic syndromes and modulation of response to azacitidine
A Valencia, E Masala, A Rossi, et al.
Ecancermedicalscience
|
January 26, 2012
The effects of continued azacitidine treatment cycles on response in higher risk patients with myelodysplastic syndromes: an update
L R Silverman, P Fenaux, G J Mufti, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 23, 2018
Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines
M Aapro, Y Beguin, C Bokemeyer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 5, 2018
Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines
M Aapro, Y Beguin, C Bokemeyer, et al.
Ecancermedicalscience
|
January 26, 2012
Azacitidine prolongs overall survival and reduces infections and hospitalizations in patients with WHO-defined acute myeloid leukaemia compared with conventional care regimens: an update
P Fenaux, G J Mufti, E Hellström-Lindberg, et al.
Leukemia
|
July 16, 2011
Role of BCL2L10 methylation and TET2 mutations in higher risk myelodysplastic syndromes treated with 5-azacytidine
M T Voso, E Fabiani, A Piciocchi, et al.
Leukemia
|
August 26, 2016
Molecular predictors of response in patients with myeloid neoplasms treated with lenalidomide
E Negoro, T Radivoyevitch, C Polprasert, et al.
Page
of 8
Search research articles
Search
Showing results (61-70 of 76) with videos related to
Sort By:
Page
of 8
Leukemia
|
February 26, 2013
A G polymorphism in the CRBN gene acts as a biomarker of response to treatment with lenalidomide in low/int-1 risk MDS without del(5q)
V Sardnal, A Rouquette, S Kaltenbach, et al.
Leukemia Research
|
February 13, 2010
Clinical management of myelodysplastic syndromes: update of SIE, SIES, GITMO practice guidelines
V Santini, P E Alessandrino, E Angelucci, et al.
Blood
|
April 16, 1998
Proliferation signaling and activation of Shc, p21Ras, and Myc via tyrosine 764 of human granulocyte colony-stimulating factor receptor
J P de Koning, A A Soede-Bobok, A M Schelen, et al.
Leukemia
|
November 7, 2013
Expression of nucleoside-metabolizing enzymes in myelodysplastic syndromes and modulation of response to azacitidine
A Valencia, E Masala, A Rossi, et al.
Ecancermedicalscience
|
January 26, 2012
The effects of continued azacitidine treatment cycles on response in higher risk patients with myelodysplastic syndromes: an update
L R Silverman, P Fenaux, G J Mufti, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 23, 2018
Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines
M Aapro, Y Beguin, C Bokemeyer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 5, 2018
Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines
M Aapro, Y Beguin, C Bokemeyer, et al.
Ecancermedicalscience
|
January 26, 2012
Azacitidine prolongs overall survival and reduces infections and hospitalizations in patients with WHO-defined acute myeloid leukaemia compared with conventional care regimens: an update
P Fenaux, G J Mufti, E Hellström-Lindberg, et al.
Leukemia
|
July 16, 2011
Role of BCL2L10 methylation and TET2 mutations in higher risk myelodysplastic syndromes treated with 5-azacytidine
M T Voso, E Fabiani, A Piciocchi, et al.
Leukemia
|
August 26, 2016
Molecular predictors of response in patients with myeloid neoplasms treated with lenalidomide
E Negoro, T Radivoyevitch, C Polprasert, et al.
Page
of 8